## malaria <br> consortium

disease control, better health

Extending seasonal malaria chemoprevention to five cycles: A feasibility and acceptability study in Cascades region, Burkina Faso

Adama Traore

2020 Annual Meeting of the American Society of Tropical Medicine \& Hygiene

## Background

- Most malaria cases and deaths in under-fives occur during the rainy season.
- In 2012, the World Health Organization (WHO) recommended seasonal malaria chemoprevention (SMC) in the Sahel subregion.
- SMC involves administration of sulphadoxinepyrimethamine and amodiaquine (SPAQ) by community health workers (CHWs) to children 3-59 months at monthly intervals during the high transmission period.
- SMC is 75 percent effective at protecting under-fives against uncomplicated and severe malaria.

WHO Policy Recommendation:
for Plasmodium falciparum Malaria Chemoprevention (SMC) rum malaria control in highly seas of the Sahel sub-region in Africa

$$
\text { March } 2012
$$

SEASONAL MALARIA CHEMOPREVENTION WITH SULFADOXINEPYRIMETHAMINE PLUS AMODIAQUINE IN CHILDREN

```
A FIEL GUIDE
```



## SMC in Burkina Faso

- Malaria is highly endemic.
- Prevalence of 17 percent among under-fives (2017-2018). ${ }^{[1]}$
- Highly seasonal transmission during the rainy season.
- SMC introduced in 2014; reached all 70 health districts in 2019.
- Four monthly SMC cycles starting in July, ending in October.
- Observed shift in the rainy season - now starts as early as June in some parts of the country.

1. National Institute of Statistics and Demography, Health Development Support Programme, National Malaria Control Programme and ICF. Malaria Indicator Survey in Burkina Faso, 2017-2018 [2018; cited 2020 Oct 06]. Available from:
http://www.insd.bf/n/contenu/enquetes recensements/enquete_palu/EIPBF 2018.pdf.


## Pilot study

## Aim

- To understand whether extending SMC to five cycles is feasible, acceptable and reduces malaria incidence in children 3-59 months.


## Design

- Pilot implementation study using mixed methods.
- Site: Mangodara district in the Cascade region.
- Region with highest malaria prevalence in Burkina Faso.
- Additional cycle implemented in June 2019.
- 30,645 children under five were estimated to be eligible for SMC in Mangodara.


Map of Burkina Faso with Mangodara and Cascades region highlighted

## Methods

| Study component | Study objectives |
| :--- | :--- |
| End-of-round survey | Assessing feasibility |
| Focus group discussions (FGDs) | Assessing acceptability |
| Key informant interviews (KIIs) | Assessing feasibility <br> Assessing acceptability |
| Health management information system (HMIS) data | Assessing malaria incidence |

## Quantitative results

- No HMIS data available in 2019 to report impact on mortality.
- No difference in coverage between five cycles in Mangodara and four cycles in the rest of the country.
- No significant difference in coverage for the fifth cycle in Mangodara.

Table 1: Proportions of eligible children 3-59 months who received SPAQ from community distributors

| Number of day one SPAQ administered during campaign | Number of children surveyed | Number of children covered (by number of cycles) | Cumulative proportion (by number of cycles) | Percent (\%) coverage (95\% CI) |
| :---: | :---: | :---: | :---: | :---: |
| Burkina Faso (22 health districts exc. Mangodara) |  |  |  |  |
| None | 3,923 | 286 | 100 | 7.3 (6.5-8.1) |
| One |  | 21 | 92.7 | 0.5 (0.3-0.8) |
| Two |  | 80 | 92.2 | 2.0 (1.6-2.5) |
| Three |  | 259 | 90.2 | 6.6 (5.9-7.4) |
| Four |  | 3,277 | 83.5 | 83.5 (82.3-84.7) |
| Burkina Faso (Mangodara heath district only |  |  |  |  |
| None | 1,063 | 29 | 100 | 2.7 (1.9-3.9) |
| One |  | 7 | 97.3 | 0.7 (0.3-1.4) |
| Two |  | 28 | 96.6 | 2.6 (1.8-3.8) |
| Three |  | 62 | 94.0 | 5.8 (4.6-7.4) |
| Four |  | 66 | 88.2 | 6.2 (4.9-7.8) |
| Five |  | 871 | 81.9 | 81.9 (79.5-84.1) |

## Qualitative results

$\left.\begin{array}{|l|l}\text { Themes } & \text { Quotes } \\ \text { Knowledge about the five-cycle campaign } & \begin{array}{l}\text { "According to my calculations, this year drugs were given earlier than last year; } \\ \text { because this year it was at the beginning of the rainy season. The first one was } \\ \text { at the beginning of the season." (Caregiver 1A) }\end{array} \\ \text { "This year we can say that there was a lot of rain and a lot of diseases. So, } \\ \text { [health workers] may have noticed that many children suffer more from malaria } \\ \text { and maybe that is why they wanted to help us and they started early to fight } \\ \text { against this disease." (Caregiver V2) }\end{array}\right\}$

| Themes | Quotes |
| :--- | :--- |
| "The Ministry [of Health] operates according to WHO guidelines. So, until WHO |  |
| recommends it, it will be difficult for us." (Policy maker P2) |  |

## Limitations

- It is not possible to assess the impact of the fifth cycle on malaria incidence due to a country-wide strike, which meant health-facility data were unavailable.
- Female CHWs were underrepresented in the FGDs.
- SMC tally sheet data were also unavailable due to the strike.


## Conclusions and recommendations

- Stakeholders at the community, regional and national level accept the five-cycle campaign.
- Respondents perceived positive health impacts of five cycles of SMC on children under five.
- Respondents outline critical challenges and key recommendations, such as the need to align the start SMC campaign with the onset of the rainy season.
- National-level stakeholders strongly recommended that further evidence is generated about the impact of a tailored SMC campaign on malaria incidence.
- Additional studies need to be conducted to show the (cost-)effectiveness of tailoring SMC to weather cycles. These were planned for 2020 but were postponed due to COVID-19.


## Acknowledgements

Ministry of Health
National Malaria Control Programme (Programme National de Lutte contre le Paludisme)

Health district staff, Mangodara
Head of Health Facility
Community distributors


Community members

## malaria consortium <br> disease control, better health



## Thank you

www.malariaconsortium.org

